Benzinga
Benzinga
Benzinga
jeudi, septembre 24

Pharming Group

PHARNASDAQ
Trade with Public
Trade with Public
$10.77
-0.49-4.35%
À la clôture: Sep 23, 5:00 PM EST
$10.97
0.201.86%
Après les heures: 9:27 AM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentComparerRapport sur les stocks

Pharming Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pharming (PHAR).

Price Target Range — 8 Quarters

Analyst Consensus — 4 Analysts

4Buy
Consensus RatingBuy# Analysts4Avg. Consensus PT$34Upside to Avg. PT+208.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 22, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$37
Sep 14, 2026HC Wainwright & Co.Joseph PantginisMaintainedBuy$37
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.
Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On Pharming with Buy Rating, Announces Price Target of $37

Canaccord Genuity analyst Whitney Ijem initiates coverage on Pharming (NASDAQ:PHAR) with a Buy rating and announces Price Target of $37.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Pharming, Lowers Price Target to $41

Oppenheimer analyst Jeff Jones reiterates Pharming (NASDAQ:PHAR) with a Outperform and lowers the price target from $42 to $41.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved